1 Research article

2 Fluoroquinolone-resistant Escherichia coli carriage in transrectal prostate biopsy

3 patients without infectious complications

- 4 Sofia Kalinen^{a†}, Heini Kallio^{a†}, Juha Knaapila^b, Teemu Kallonen^{c,a}, Eveliina Munukka^{a,c},
- 5 Tarja Lamminen^b, Pentti Huovinen^{a,b}, Peter J. Boström^b, Antti J. Hakanen^{c,a} and Marianne
- 6 Gunell^{c,a}*
- ⁷ ^aMedical Microbiology and Immunology, Institute of Biomedicine, University of Turku,
- 8 Turku, Finland;
- ⁹ ^bDepartment of Urology, Turku University Hospital, Turku, Finland;
- ¹⁰ ^cDepartment of Clinical Microbiology, Laboratory Division, Turku University Hospital,
- 11 Turku, Finland.
- 12
- ¹³ *Corresponding author. Clinical microbiology, Turku University Hospital, Kiinamyllynkatu
- 14 10, 20520 Turku, Finland, tel: +358-46-922 1871, email: marianne.gunell@tyks.fi
- 15 *†*These authors contributed equally to this article.
- 16
- 17 Running title: FQ-resistant *E. coli* in TRUS-Bx patients
- 18 Keywords: Ciprofloxacin-resistant, *E. coli*, TRUS-Bx, prophylaxis, resistance mechanisms

20 Abstract

21 Fluoroquinolones are a commonly used prophylaxis in transrectal ultrasound-guided 22 prostate biopsy (TRUS-Bx), even though fluoroquinolone-resistant Escherichia coli has 23 been associated with infectious complications after TRUS-Bx. The present study describes fluoroguinolone resistance mechanisms and antimicrobial susceptibility among intestinal E. 24 25 coli, isolated from TRUS-Bx patients in a prospective study showing very few infectious 26 prostate biopsy adverse events. This Multi-IMPROD sub-study included a total of 336 patients who received either ciprofloxacin, levofloxacin, or fosfomycin as prophylaxis 27 28 before TRUS-Bx. E. coli could be cultured from 278 fecal swab samples, and 27 (9.7%) of 29 these showed resistance to ciprofloxacin, and 14 (5.0%) were susceptible with increased 30 exposure (I). Chromosomal and transferable fluoroquinolone resistance mechanisms were 31 found among ciprofloxacin non-susceptible isolates, but both *qnr* genes and single *gyrA* 32 mutations were found also among the ciprofloxacin-susceptible E. coli population. Low-33 level fluoroquinolone resistance is commonly associated with ESBL production in Enterobacterales. However, ESBL and qnr genes were not associated in our material, 14 34 isolates were ESBL producers and only 14.3% of them had the *gnr* gene, although 85.7% 35 36 of the ESBL producers were ciprofloxacin non-susceptible. In the Multi-IMPROD substudy, 37 only two mild urinary tract infections were reported, indicating that the antimicrobial susceptibility or resistance pattern of *E. coli* does not correlate with the onset of post-38 biopsy adverse events. We conclude that in our clinical settings, ciprofloxacin and 39 levofloxacin prophylaxis is effective, and no severe post-biopsy infections were detected 40 41 despite the intestinal colonization of genotypically and phenotypically fluoroquinolone-42 resistant E. coli.

43

44 Introduction

Prostate cancer is one of the most common cancer types in men, especially in Western 45 46 countries. A prostate cancer diagnosis is based on transrectal ultrasound-guided prostate 47 biopsy (TRUS-Bx) which is an invasive procedure, and antimicrobial prophylaxis is a common practice to lower the risk for infectious adverse events. Fluoroguinolones are 48 49 widely used prophylaxis in prostate biopsy procedures, due to their good penetration to 50 prostate tissue (1). Fluoroquinolone resistance has emerged globally during the last 51 decades, and both fluoroquinolone-resistant *Escherichia coli* and isolates with reduced 52 susceptibility have increasingly reported to cause sepsis or other infectious adverse events 53 after prostate biopsy procedure (2-6). In Finland, fluoroquinolones are very common per 54 oral treatment for urinary tract infections in men. Fluoroquinolone resistance in both urine and blood *E. coli* isolates has increased during the last decade, being 15.1% and 10.8%, 55 56 respectively in Finres data of 2020 (7). The percentage of ESBL-producing E. coli has also 57 increased during the last decade being 6.5% in men's urine isolates and 6.6% in blood isolates in 2020 (7). In Enterobacterales, low-level fluoroquinolone resistance has been 58 associated with ESBL production (8-11), and in Finland, 2.3% of the urine E. coli isolates 59 60 were both ESBL producers and fluoroquinolone-resistant in 2020 (7). Low-level 61 fluoroquinolone resistance is mainly caused by plasmid-mediated quinolone resistance (PMQR) determinants like *gnr* genes whereas high-level resistance is caused by several 62 chromosomal mutations in the quinolone resistance determining region (QRDR) of DNA 63 64 gyrase (gyrA/gyrB) and topoisomerase IV genes (parC/parE) (12-14). In E. coli, resistance 65 to fluoroquinolones is highly associated with mutations in gyrA (12). In the present study, 66 we determined the correlation between prostate biopsy adverse events, fluoroquinolone 67 resistance mechanisms and antimicrobial susceptibility among intestinal E. coli isolated 68 from fecal swab samples from men undergoing TRUS-Bx procedure in Finland.

69 Methods

70 Study population. This study is a substudy of IMPROD (Improved Prostate Cancer 71 Diagnosis – Combination of Magnetic Resonance Imaging (MRI) and Biomarkers, NCT02241122) multi-center study (15). A prostate cancer screen with TRUS-Bx was 72 73 performed for patients included in this study and a rectal swab sample was taken during the biopsy procedure. Between March 2015 and May 2017, a total of 336 rectal swab 74 75 samples were collected from four hospitals in Finland: Helsinki University Hospital, 58 samples; Tampere University Hospital, 59 samples; Satakunta Central Hospital, 87 76 77 samples; and Turku University Hospital, 132 samples. Levofloxacin was used as 78 antimicrobial prophylaxis in Turku, and ciprofloxacin in all the other study sites. In Helsinki, 79 patients who had traveled abroad within three months before the TRUS-Bx received fosfomycin instead of ciprofloxacin. 80 81 Bacterial cultures. Swab samples were cultured on ChromAgar Orientation plate (Becton 82 Dickinson, Heidelberg, Germany) and 5 µg-ciprofloxacin disk (OXOID, Thermo Scientific, Helsinki, Finland) was placed on top of the culture to select the patient's most resistant E. 83 coli strain. After the overnight incubation at 35 °C, two to three bacterial colonies with E. 84 85 coli morphology (mauve to light purple colonies) were selected preferably near to the ciprofloxacin disk and pure cultures were made from these on CLED plates (Becton 86 87 Dickinson, Heidelberg, Germany). Maldi-TOF (Bruker, Berlin, Germany) was used for species identification of the isolated strains. Only E. coli isolates were studied further. 88 89 Antimicrobial susceptibility testing. Antimicrobial susceptibility testing was performed with 90 the disk diffusion method, according to EUCAST guidelines (16). Following antimicrobial 91 disks were used: ciprofloxacin 5 µg, levofloxacin 5 µg, cefotaxime 5 µg, ceftazidime 10 µg, cefoxitin 30 µg, meropenem 10 µg, ampicillin 10 µg, amoxicillin-clavulanic acid 10/20 µg, 92 mecillinam 10 µg, nitrofurantoin 300 µg, trimethoprim 5 µg, and trimethoprim-93

94	sulfamethoxazole 25 μ g (OXOID, Thermo Scientific, Helsinki, Finland). Antimicrobial
95	susceptibility profiles of each <i>E. coli</i> isolates were determined according to EUCAST
96	clinical breakpoint table version 11.0 2021 (17). E. coli ATCC 25922 was used as a control
97	strain in antimicrobial susceptibility testing.
98	PCR amplification and sequencing of chromosomal gyrA and parC gene mutations.
99	Fluoroquinolone resistance mechanisms were studied in all E. coli isolates with a
100	ciprofloxacin (CIP) disk inhibition zone ≤30mm. PCR amplification of <i>gyrA</i> and <i>parC</i> genes
101	were performed with primers described in Table 1. The gyrA/parC PCR reaction (50 μ L)
102	consisted of 0.2 pmol/µL of each primer, 0.03 U/µL AmpliTaq Gold DNA polymerase, 5 µL
103	AmpliTaq Gold buffer, 2 mM MgCl $_2$ (Thermo Fisher Scientific Oy, Vantaa, Finland), and
104	0.2 mM dNTP mix (Life Technologies Europe, Espoo, Finland). The PCR program
105	consisted of an initial denaturation at 94°C for 10 minutes, then 37 cycles of DNA
106	denaturation at 94°C for 30 seconds, primer annealing at 55°C for 30 seconds, and
107	extension at 72°C for 90 seconds. PCR-products were purified enzymatically with
108	Exonuclease I- and FastAp Thermosensitive alkaline phosphatase -enzymes (Thermo
109	Fisher Scientific Oy, Vantaa, Finland), and sequenced with BigDye v.3.1 sequencing using
110	ABI3730xI DNA Analyzer at Institute for Molecular Medicine (FIMM, Helsinki, Finland).
111	Detection of plasmid-mediated quinolone resistance genes. Transferable plasmid-
112	mediated quinolone resistance (PMQR) qnr genes were screened for all the E. coli isolates
113	with a ciprofloxacin disk inhibition zone ≤30mm. In addition, 34/90 randomly selected
114	isolates with a ciprofloxacin inhibition zone >30mm were studied with previously reported
115	primers and protocols (18).
116	Detection of ESBL genes. Possible ESBL producers were screened according to EUCAST
117	guidelines on the detection of Resistance mechanisms (19). ESBL + AmpC confirmation
118	Kit (Rosco Diagnostics) was used to confirm ESBL production from <i>E. coli</i> isolates with

119 reduced cefotaxime and ceftazidime susceptibility, inhibition zone <21 and <22mm, 120 respectively. ESBL genes (*bla*_{CTX-M} *bla*_{SHV} and *bla*_{TEM}) were screened from these same 121 isolates using previously described primers and PCR protocols (20). 122 Results Antimicrobial susceptibility profiles. E. coli could be isolated from 278 patient samples (out 123 124 of 336 fecal samples). The highest resistance rates were detected against ampicillin and 125 amoxicillin-clavulanate (27.7% and 24.1%, respectively), also trimethoprim resistance was quite common (14.0%) (Figure 1). Totally 27 (9.7%) E. coli strains were ciprofloxacin-126 127 resistant i.e. disk inhibition zone was <22mm and 14 (5.0 %) strains were ciprofloxacin-128 susceptible with increased exposure (I, CIP inhibition zone 22-24mm), according to the 129 2021 EUCAST breakpoints (17). Furthermore 22 (7.9%) E. coli strains were levofloxacinresistant (R) (Figure 1). With correlation to given prophylaxis, 11 (9.6%) isolates from the 130 levofloxacin group were resistant to both ciprofloxacin and levofloxacin, and six (5.3%) and 131 132 four (3.5%) were ciprofloxacin- and levofloxacin-susceptible with increased exposure (I), respectively. Among the ciprofloxacin group, 16 (9.8%) and 11 (6.7%) isolates were 133 ciprofloxacin and levofloxacin R, respectively, and eight (4.9%) and 11 (6.7%) isolates 134 were ciprofloxacin and levofloxacin I, respectively. 135 Resistance against cefotaxime and ceftazidime was detected in 14 (5.0%) and 13 (4.7%) 136 137 E. coli isolates. Of the ciprofloxacin-resistant E. coli isolates, nine (3.2%) were cefotaximeresistant, and eleven (4.0%) showed co-resistance to trimethoprim. These eleven strains 138 139 were also resistant to ampicillin and sulfamethoxazole-trimethoprim. Four of these were 140 also gentamicin-resistant and three of these were ESBL producing strains. Ten 141 ciprofloxacin-resistant E. coli (3.6%) were also ESBL producers and five (1.8%) isolates 142 were both trimethoprim-resistant and ESBL producers. Antimicrobial susceptibility results 143 from all tested antimicrobials are presented in Figure 1.

144 Fluoroguinolone resistance mechanisms and ESBL producers. Fluoroguinolone resistance 145 mechanisms were found in all fluoroquinolone-non-susceptible isolates, i.e. CIP disk 146 inhibition zone <25mm (17). Of the ciprofloxacin-resistant isolates, 23 had point mutations 147 in the QRDR of both gyrA and parC, and four had point mutations only in gyrA. The most common gyrA mutation was S83L + D87N -double mutation found in 20 isolates, nine of 148 149 these had also S80I + E84G –double mutation, and ten had S80I –single mutation in parC 150 (Figure 2). Of the 14 *E. coli* isolates being ciprofloxacin I (susceptible with increased dose, according to EUCAST (17), disk inhibition zone 22-24mm), ten had S83L -single mutation 151 152 and one had D87Y –single mutation in the QRDR of gyrA, and three isolates had only gnr 153 gene (qnrA/B) as their only fluoroquinolone-resistance mechanism detected. 154 Fluoroquinolone resistance mechanisms were also found among ciprofloxacin-susceptible 155 isolates. A total of seven isolates with ciprofloxacin inhibition zone between 25-29mm had a single gyrA mutation, and 31 isolates had gnr gene. The distribution of fluoroquinolone 156 157 resistance mechanisms among the tested *E. coli* population is presented in Figure 2. According to EUCAST Detection of resistance mechanisms guideline (19), 15 E. coli 158 isolates (5.4%) were ESBL producers, nine of these were positive for bla_{CTX-M} gene, four 159 for *bla*_{CTX-M}+*bla*_{TEM}, and one strain for *bla*_{SHV}+*bla*_{TEM}. One screening positive isolate did 160 161 not have any of these three ESBL genes analyzed. Of the ESBL *E. coli* strains, ten were 162 ciprofloxacin-resistant and had chromosomal mutations, two were ciprofloxacin susceptible with increased dose, one of them had *qnrS* gene and the other had a single *gyrA* mutation. 163 Two of the ESBL strains were ciprofloxacin-susceptible, but one of these had a single gyrA 164 165 mutation. The distribution of ESBL genes and fluoroquinolone resistance mechanisms is 166 presented in Figure 2.

Fluoroquinolone susceptibility and resistance mechanisms in correlation to post-biopsy
 adverse events

In the Multi-IMPROD study, only 12 minor post-biopsy adverse events were reported.²¹ 169 170 The list of complications, prophylaxis, and microbiological findings, including ciprofloxacin 171 susceptibility and possible resistance mechanisms of these 12 patients' are presented in 172 Table 2. 173 Discussion In the present study, the antimicrobial susceptibility and fluoroquinolone resistance 174 175 mechanisms of intestinal *E. coli*, isolated from faecal swab samples from men undergoing prostate biopsy procedures were analysed. Post-biopsy infections are a common side 176 177 effect of prostate biopsy procedures, and especially fluoroquinolone-resistant and 178 multidrug-resistant E. coli has been reported of being the main factor for infectious adverse 179 events (2-5, 22). Our results showed that 14.7% of the tested E. coli strains were ciprofloxacin non-susceptible, and 85.3% were susceptible according to EUCAST 180 181 breakpoints (17). If CLSI breakpoints would have been used the number of ciprofloxacin-182 resistant strains would have been the same (CIP \leq 21mm), whereas the ciprofloxacin I isolates would have increased from 14 to 19 isolates (CIP 22-25mm vs. CIP 22-24mm) 183 (23). Resistance to levofloxacin was more common in the study population who got 184 185 levofloxacin prophylaxis than in ciprofloxacin prophylaxis group (9.6% vs. 6.7%, 186 respectively), whereas ciprofloxacin resistance was practically equal in both groups (9.6%) 187 vs. 9.8%, respectively). Of the ciprofloxacin-resistant E. coli, 4.0% showed co-resistance to 188 trimethoprim, 3.6% of were ciprofloxacin-resistant and ESBL producers, and 1.8% were 189 ciprofloxacin- and trimethoprim-resistant and ESBL producers. Compared to overall 190 susceptibility levels of *E. coli* isolates in Finland in 2020, fluoroguinolone resistance among 191 the study population was higher compared to invasive isolates (10.8%), but equal to 192 resistance levels in urine isolates (15.1%) (7). ESBL percentage among the intestinal E. 193 *coli* isolates was somewhat higher, 5.4%, compared to the earlier reported ESBL carriage

194 rate (4.7%) in Finland (24), but lower compared to ESBL-positivity rate in urine E. coli – 195 isolates (6.5%) (7). In addition, resistance to trimethoprim was lower, whereas multidrug 196 resistance was more common compared to that reported in Finres 2020 (7). 197 To become a high-level fluoroquinolone-resistant, bacterial strain needs to have mutations in both QRDR of *gyrA* and *parC*, however mutation even in one of these gene targets, 198 199 S83L in gyrA, S80I in parC, and D87N in gyrA can cause a clinically relevant 200 fluoroquinolone resistance in *E. coli* (25). In our study, double gyrA+parC mutations were detected only in high-level resistant isolates whereas single qyrA mutations were detected 201 202 even phenotypically ciprofloxacin-susceptible isolates. EUCAST has started using the term 203 ATU (Area of Technical Uncertainty) to warn laboratories that, there can be interpretative 204 difficulties with susceptibility test results in this area, and susceptibility interpretation should be carefully evaluated (26). According to EUCAST breakpoints for ciprofloxacin 205 (17), the ATU area is situated between the resistant and susceptible populations (22-206 207 24mm), i.e. I area, and includes the isolates which can be considered susceptible with 208 increased exposure. As we show in Figure 2, isolates within the area of technical uncertainty, have chromosomal gyrase mutations, indicating that it is justified to consider 209 210 these isolates rather resistant than susceptible. PMQR determinants like *gnr* genes are 211 linked to low-level fluoroguinolone resistance but these genes also enhance the selection 212 of high-level resistance, furthermore, the *gnr* genes are also easily missed until further 213 mechanisms are acquired and detected (11-12,14, 27-28). We show that the gnr genes 214 were detected among ciprofloxacin-resistant, ciprofloxacin I, and ciprofloxacin-susceptible 215 strains, indicating that gnr genes do not necessarily have a clinical relevance without 216 additional resistance mechanisms (25). PMQR genes are associated with the same 217 plasmids as ESBL genes (9-11, 27) and there are reports on post-biopsy infections linked 218 to ESBL *E. coli* isolates with co-resistance to fluoroquinolones (29). In our study, 85.7% of

219 the ESBL strains had chromosomal mutations in QRDR and only one ESBL strain had a 220 PMQR gene as the only fluoroquinolone resistance mechanism, indicating that ESBL-221 producing strains and strains with qnr genes were not associated in our material. In 222 addition, among the tested ciprofloxacin-susceptible *E. coli* isolates with disk inhibition 223 zone 31-36mm, no fluoroquinolone resistance determinants were detected, as expected. 224 Despite the ciprofloxacin and multidrug resistance detected in our study population, no 225 severe post-biopsy infections were reported in the Multi-IMPROD study (21). It is known, 226 that the use of fluoroguinolones increases the risk for intestinal colonization of 227 fluoroquinolone-resistant *E. coli*, and further post-biopsy infectious complications (6,30). In 228 the present study, there were both phenotypically ciprofloxacin-resistant *E. coli* and 229 isolates with susceptible phenotype but having fluoroquinolone resistance mechanisms, 230 and despite this, only two mild UTI cases were reported. One of them had ciprofloxacinsusceptible E. coli in a swab sample, and the other had ciprofloxacin I E. coli with a single 231 232 gyrA mutation, indicating that fluoroquinolone resistance alone does not explain the possible adverse events after TRUS-Bx. There are reports on certain *E. coli* clones, such 233 as ST131 that have spread widely and have caused severe infections (3), and thus further 234 studies are needed to evaluate the role of virulence factors and other resistance 235 236 mechanisms such as efflux pumps, in post-biopsy infections.

237 **Conclusion:**

We show in this study that fluoroquinolone resistance mechanisms, both the *qnr* genes

and gyrA mutations, were also found among the ciprofloxacin-susceptible E. coli

population and that ESBL and transferable *qnr* genes were not associated in our material.

241 We conclude that the onset of post-biopsy adverse events did not correlate with

antimicrobial susceptibility, since no severe post-biopsy infections were detected despite

- the intestinal colonization of genotypically and phenotypically fluoroquinolone-resistant *E*.
- 244 *coli*.

246 Acknowledgments

247 We thank Minna Lamppu for her skillful technical assistance with cultured *E. coli* isolates

248 Funding

- 249 This study was funded by the Sigrid Juselius Foundation (for Peter J. Boström), and
- 250 Finnish Governmental Special Funding, The Cancer Foundation Finland, University of
- 251 Turku Combined Research Funding, and the Turku University Hospital Foundation (for
- 252 Juha Knaapila).

253 Conflict of Interest

All authors declare no conflict of interest regarding this publication.

255 Transparency declarations

None to declare

257 **References**

- **1.** Zani EL, Clark OA, Rodrigues Netto N Jr. Antibiotic prophylaxis for transrectal prostate
- biopsy. Cochrane Database Syst Rev 2011;(5):CD006576. doi:
- 260 10.1002/14651858.CD006576.pub2. PMID: 21563156.
- 261 **2.** Young JL, Liss MA, Szabo RJ. Sepsis due to fluoroquinolone-resistant *Escherichia coli*
- after transrectal ultrasound-guided prostate needle biopsy. *Urology* 2009;74(2):332-8. doi:

263 10.1016/j.urology.2008.12.078. Epub 2009 May 22. PMID: 19464041.

- **3.** Williamson DA, Roberts SA, Paterson DL, Sidjabat H, Silvey A, Masters J, Rice M,
- 265 Freeman JT. Escherichia coli bloodstream infection after transrectal ultrasound-guided
- 266 prostate biopsy: implications of fluoroquinolone-resistant sequence type 131 as a major
- 267 causative pathogen. *Clin Infect Dis* 2012;54(10):1406-12. doi: 10.1093/cid/cis194. Epub
- 268 2012 Mar 14. PMID: 22419681.
- 269 **4.** Bokhorst LP, Lepistö I, Kakehi Y, Bangma CH, Pickles T, Valdagni R, Alberts AR,

270 Semjonow A, Strolin P, Montesino MF, Berge V, Roobol MJ, and Rannikko A.

- 271 Complications after prostate biopsies in men on active surveillance and its effects on
- 272 receiving further biopsies in the Prostate cancer Research International: Active Surveillance

273 (PRIAS) study. *BJU Int* 2016; 118:366-371. doi: 10.1111/bju.13410 [doi].

- **5.** Steensels D, Slabbaert K, De Wever L, Vermeersch P, Van Poppel H, and Verhaegen J.
- 275 Fluoroquinolone-resistant *E. coli* in intestinal flora of patients undergoing transrectal
- 276 ultrasound-guided prostate biopsy--should we reassess our practices for antibiotic
- 277 prophylaxis? *Clin Microbiol Infect* 2012 18:575-581. doi: 10.1111/j.1469-0691.2011.03638.x
- 278 [doi].
- **6.** Kalalahti I, Huotari K, Lahdensuo K, Tarkka E, Santti H, Rannikko A, Pätäri-Sampo A.
- 280 Rectal *E. coli* above ciprofloxacin ECOFF associate with infectious complications following
- 281 prostate biopsy. *Eur J Clin Microbiol Infect Dis* 2018 Jun;37(6):1055-1060. doi:
- 282 10.1007/s10096-018-3217-7. Epub 2018 Mar 2. PMID: 29500572.

- 283 **7.** Räisänen K, Ilmavirta H, Vuento R, Hakanen AJ, Salmenlinna S, Gunell M, Jalava J,
- 284 Rantakokko-Jalava K, Wuorela M, Hyyryläinen HL, Mentula S, Pätäri-Sampo A, Toropainen
- 285 M, Seiskari T. Bakteerien mikrobilääkeresistenssi Suomessa: Finres 2020. Työpaperi:
- 286 2021_029. (In Finnish, Figures also in English). THL Terveyden ja hyvinvoinninlaitos.
- 287 https://urn.fi/URN:ISBN:978-952-343-758-6
- 288 **8.** Cattoir V, Poirel L, Rotimi V, Soussy CJ, Nordmann P. Multiplex PCR for detection of
- 289 plasmid-mediated quinolone resistance *qnr* genes in ESBL-producing enterobacterial
- isolates. J Antimicrob Chemother 2007; Volume 60, Issue 2: 394–
- 291 397, <u>https://doi.org/10.1093/jac/dkm204</u>
- Jiang Y, Zhou Z, Qian Y, Wei Z, Yu Y, Hu S, Li L. Plasmid-mediated quinolone resistance
 determinants *qnr* and *aac(6')-lb-cr* in extended-spectrum β-lactamase-
- 294 producing Escherichia coli and Klebsiella pneumoniae in China. J Antimicrob Chemother
- 295 2008; Volume 61, Issue 5: 1003–1006, <u>https://doi.org/10.1093/jac/dkn063</u>
- Veldman K, Dierikx C, van Essen-Zandbergen A, van Pelt W, Mevius D. Characterization of
 multidrug-resistant, *qnrB2*-positive and extended-spectrum-β-lactamase-
- 298 producing Salmonella Concord and Salmonella Senftenberg isolates. J Antimicrob
- 299 Chemother 2010; Volume 65, Issue 5: 872–875, https://doi.org/10.1093/jac/dkq049
- 300 **11.** Gunell M, Aulu L, Jalava J, Lukinmaa-Åberg S, Österblad M, Ollgren J, Huovinen P,
- 301 Siitonen A, Hakanen AJ. Cefotaxime-resistant Salmonella enterica in travelers returning
- from Thailand to Finland. *Emerg Infect Dis* 2014 Jul;20(7): 1214-7. doi:
- 303 10.3201/eid2007.131744. PMID: 24960266; PMCID: PMC4073843.
- **12.** Hooper DC. Mechanisms of fluoroquinolone resistance. *Drug Resist Updat* 1999;2(1):38-
- 305 55. doi: 10.1054/drup.1998.0068. PMID: 11504468.
- **13.** Gunell M, Webber MA, Kotilainen P, Lilly AJ, Caddick JM, Jalava J, Huovinen P, Siitonen
- 307 A, Hakanen AJ, Piddock LJ. Mechanisms of resistance in nontyphoidal Salmonella enterica
- 308 strains exhibiting a nonclassical quinolone resistance phenotype. Antimicrob Agents
- 309 *Chemother* 2009;53(9):3832-6. doi: 10.1128/AAC.00121-09. Epub 2009 Jul 13. PMID:
- 310 19596880; PMCID: PMC2737843.

- **14.** Hooper DC, Jacoby GA. Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action
- and Resistance. *Cold Spring Harb Perspect Med* 2016; Sep 1;6(9):a025320. doi:
- 313 10.1101/cshperspect.a025320. PMID: 27449972; PMCID: PMC5008060.
- **15.** Knaapila J, Kallio H, Hakanen AJ, Syvänen K, Ettala O, Kähkönen E, Lamminen T,
- 315 Seppänen M, Jambor I, Rannikko A, Riikonen J, Munukka E, Eerola E, Gunell M, Boström
- 316 PJ. Antibiotic susceptibility of intestinal *Escherichia coli* in men undergoing transrectal
- 317 prostate biopsies: a prospective, registered, multicentre study. *BJU Int* 2018;122(2):203-
- 210. doi: 10.1111/bju.14198. Epub 2018 Apr 6. PMID: 29533507.
- **16.** European Committee on Antimicrobial Susceptibility Testing. 2015. Antimicrobial
- 320 susceptibility testing. EUCAST disk diffusion method. Manual version 5.0.
- 321 https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/Man
- 322 ual v 5.0 EUCAST Disk Test.pdf
- **17.** European Committee on Antimicrobial Susceptibility Testing. 2021. The European
- 324 Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of
- 325 MICs and zone diameters, version 11.0.
- 326 <u>https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_11.0</u>
- 327 Breakpoint Tables.pdf
- **18.** Robicsek A, Strahilevitz J, Sahm DF, Jacoby GA, Hooper DC. qnr prevalence in
- 329 ceftazidime-resistant *Enterobacteriaceae* isolates from the United States. *Antimicrob*
- 330 *Agents Chemother* 2006;50(8):2872-4. doi: 10.1128/AAC.01647-05. PMID: 16870791;
- 331 PMCID: PMC1538681.
- **19.** European Committee on Antimicrobial Susceptibility Testing. 2017. The EUCAST guideline
- on detection of resistance mechanisms, version 2.0.
- 334 https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/
- 335 <u>EUCAST detection of resistance mechanisms 170711.pdf</u>
- **20.** Nyberg SD, Österblad M, Hakanen AJ, Huovinen P, Jalava J, and The Finnish Study Group
- 337 For Antimicrobial Resistance. Detection and molecular genetics of extended-spectrum

338	beta-lactamases among cefuroxime-resistant Escherichia coli and Klebsiella spp. isolates
339	from Finland, 2002-2004. Scand J Infect Dis 2007; 39:417-424. doi: 777680054 [pii].
340	21. Knaapila J, Gunell M, Syvänen K, Ettala O, Kähkönen E, Lamminen T, Seppänen M,
341	Jambor I, Rannikko A, Riikonen J, Munukka E, Eerola E, Hakanen AJ, and Boström PJ.
342	Prevalence of Complications Leading to a Health Care Contact After Transrectal Prostate
343	Biopsies: A Prospective, Controlled, Multicenter Study Based on a Selected Study Cohort.
344	Eur Urol Focus 2019;5(3):443-448. doi: 10.1016/j.euf.2017.12.001. Epub 2017 Dec 20.
345	PMID: 29275146.
346	22. Williamson DA, Barrett LK, Rogers BA, Freeman JT, Hadway P, Paterson DL. Infectious
347	complications following transrectal ultrasound-guided prostate biopsy: new challenges in
348	the era of multidrug-resistant Escherichia coli. Clin Infect Dis 2013;57(2):267-74. doi:
349	10.1093/cid/cit193. Epub 2013 Mar 26. PMID: 23532481.
350	23. Clinical and Laboratory Standards Institute. 2020. Performance Standards for Antimicrobial
351	Susceptibility testing: M100-ED30:2020. CLSI, Wayne, PA, USA.
352	24. Ny S, Kozlov R, Dumpis U, Edquist P, Gröndahl-Yli-Hannuksela K, Kling AM, Lis DO,
353	Lubbert C, Pomorska-Wesolowska M, Palagin I, Vilde A, Vuopio J, Walter J, Wisell KT and
354	NoDARS ESBL-carrier working group. Large variation in ESBL-producing Escherichia coli
355	carriers in six European countries including Russia. Eur J Clin Microbiol Infect Dis 2018;
356	37:2347-2354. doi: 10.1007/s10096-018-3382-8 [doi].
357	25. Huseby DL, Pietsch F, Brandis G, Garoff L, Tegehall A, Hughes D. Mutation Supply and
358	Relative Fitness Shape the Genotypes of Ciprofloxacin-Resistant Escherichia coli. Mol Biol
359	<i>Evol</i> 2017;34(5):1029-1039. doi: 10.1093/molbev/msx052. PMID: 28087782; PMCID:
360	PMC5400412.
361	26. European Committee on Antimicrobial Susceptibility Testing. 2019. Area of Technical
362	Uncertainty (ATU) in antimicrobial susceptibility testing.
363	https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/AT
364	<u>U/Area_of_Technical_Uncertainty - guidance_2019.pdf</u>

- **27.** Poirel L, Cattoir V, Nordmann P. Is plasmid-mediated quinolone resistance a clinically
- 366 significant problem? *Clin Microbiol Infect* 2008;14(4):295-7. doi: 10.1111/j.1469-
- 367 0691.2007.01930.x. Epub 2008 Jan 7. PMID: 18190576.
- 368 **28.** Gunell M, Hakanen AJ, Jalava J, Huovinen P, Österblad M. Hidden qnrB12 gene in a
- 369 Finnish faecal microbiota isolate from 1994. *J Antimicrob Chemother* 2009;64(4):861-2. doi:
- 10.1093/jac/dkp304. Epub 2009 Aug 19. PMID: 19692413.
- 371 **29.** Korkmaz N, Gurbuz Y, Sandikci F, Kul G, Tutuncu EE, Sencan I. The Role of Ciprofloxacin
- 372 Resistance and Extended-spectrum beta-lactamase (ESBL) Positivity in Infective
- 373 Complications Following Prostate Biopsy. *Urol J*, 2020;17(2):192-197. doi:
- 374 10.22037/uj.v0i0.4755. PMID: 31364100.
- **30.** Taylor S, Margolick J, Abughosh Z, Goldenberg SL, Lange D, Bowie WR, Bell R, Roscoe D,
- 376 Machan L, Black P. Ciprofloxacin resistance in the faecal carriage of patients undergoing
- transrectal ultrasound guided prostate biopsy. *BJU Int* 2013;111(6):946-53. doi:
- 378 10.1111/j.1464-410X.2012.11637.x. Epub 2013 Mar 6. PMID: 23464844.

Table 1. Primers used in *gyrA* and *parC* PCR and Sanger sequencing

Primer	Target	Sequence (5'-3')
Ecoli_gyrA_307_f	gyrA	AAGCCGGTACACCGTCGCGTACTT
Ecoli_gyrA_570 r	gyrA	TTTCGCCAGACGGATTTCCG
Ecoli_parC_172_f	parC	GTCTGAACTGGGCCTGAATGC
Ecoli_parC_321_r	parC	AGCGGATAACGGTAAGAGAACGG

- Table 2. Patients with post-biopsy adverse events, used prophylaxis, ciprofloxacin
- susceptibility testing results and resistance mechanisms detected.

Sample ID	Prophylaxis	Adverse	E. coli	CIP disk	Susceptibility	FQ-
		event		inhibition	interpretation	resistance
				zone (mm)		mechanism
TA-009	Ciprofloxacin	mild UTI	yes	24	1	S83L
TU-062	Levofloxacin	hematuria	yes	27	S	D87N
HE-056	Ciprofloxacin	hematuria	yes	28	S	qnrA
PO-071	Ciprofloxacin	urine retention	yes	28	S	-
PO-055	Ciprofloxacin	mild UTI	yes	29	S	-
TU-010	Levofloxacin	hematuria	yes	30	S	-
TU-054	Levofloxacin	hematuria	yes	30	S	-
HE-053	Ciprofloxacin	hematuria	yes	31	S	-
PO-075	Ciprofloxacin	urinary retention	yes	31	S	-
TU-146	Levofloxacin	rectal bleeding	yes	31	S	-

TU-026	Levofloxacin	hematuria	yes	32	S	-
HE-047	Ciprofloxacin	hematuria/	no	nd	nd	nd
	•					
		urinary				
		retention				

383

- Figure 1. Antimicrobial susceptibility profiles of 278 *E. coli,* isolated from fecal swab
- samples taken from men undergoing TRUS-Bx

387	Figure 2. Fluoroquinolone (FQ) resistance mechanisms and ESBL genes detected among 276 E. coli isolates with ciprofloxacin
388	(CIP) disk inhibition zone 6-30 mm. A dashed black line with R represents EUCAST and CLSI breakpoint (16, 23) for CIP-resistant
389	isolates. A dashed line with black S represents the EUCAST breakpoint and a grey dashed line with S represents the CLSI
390	breakpoint for CIP susceptible isolates.
391	
392	
393	
394	
395	
396	
397	
398	
399	
400	R= resistant; S= susceptible

401 *Randomly selected 34 isolates with disk inhibition zone 31-36mm were tested for *qnr* genes



